WO2002053139A3 - Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders - Google Patents
Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders Download PDFInfo
- Publication number
- WO2002053139A3 WO2002053139A3 PCT/US2001/045863 US0145863W WO02053139A3 WO 2002053139 A3 WO2002053139 A3 WO 2002053139A3 US 0145863 W US0145863 W US 0145863W WO 02053139 A3 WO02053139 A3 WO 02053139A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- receptor antagonist
- treatment
- amino acid
- excitatory amino
- neurological disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002241565A AU2002241565A1 (en) | 2001-01-05 | 2001-12-20 | Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25992301P | 2001-01-05 | 2001-01-05 | |
US60/259,923 | 2001-01-05 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2002053139A2 WO2002053139A2 (en) | 2002-07-11 |
WO2002053139A3 true WO2002053139A3 (en) | 2002-08-22 |
WO2002053139A8 WO2002053139A8 (en) | 2003-11-13 |
Family
ID=22987001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/045863 WO2002053139A2 (en) | 2001-01-05 | 2001-12-20 | Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002241565A1 (en) |
WO (1) | WO2002053139A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101825972B1 (en) | 2010-10-15 | 2018-02-06 | 콘테라 파르마 에이피에스 | Combinations of serotonin receptor agonists for treatment of movement disorders |
PT2838517T (en) | 2012-04-18 | 2018-01-04 | Contera Pharma Aps | Orally available pharmaceutical formulation suitable for improved management of movement disorders |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5721252A (en) * | 1994-10-05 | 1998-02-24 | Eli Lilly And Company | 5HT1F agonists for the treatment of migraine |
WO1998045270A1 (en) * | 1997-04-07 | 1998-10-15 | Eli Lilly And Company | Pharmacological agents |
WO2001001972A2 (en) * | 1999-07-06 | 2001-01-11 | Eli Lilly And Company | SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE |
-
2001
- 2001-12-20 AU AU2002241565A patent/AU2002241565A1/en not_active Abandoned
- 2001-12-20 WO PCT/US2001/045863 patent/WO2002053139A2/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5721252A (en) * | 1994-10-05 | 1998-02-24 | Eli Lilly And Company | 5HT1F agonists for the treatment of migraine |
WO1998045270A1 (en) * | 1997-04-07 | 1998-10-15 | Eli Lilly And Company | Pharmacological agents |
WO2001001972A2 (en) * | 1999-07-06 | 2001-01-11 | Eli Lilly And Company | SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE |
Also Published As
Publication number | Publication date |
---|---|
WO2002053139A2 (en) | 2002-07-11 |
WO2002053139A8 (en) | 2003-11-13 |
AU2002241565A1 (en) | 2002-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003015713A3 (en) | Treatment of glial tumors with glutamate antagonists | |
WO2001087328A3 (en) | Interleukin-1 inhibitors in the treatment of diseases | |
WO2002032374A3 (en) | Methods for treating il-18 mediated disorders | |
MXPA02001306A (en) | Pharmaceutical compositions for the treatment of cns and other discorders. | |
EP0900568A3 (en) | AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy | |
WO2005102338A8 (en) | Method of treating neuropathic pain using a crth2 receptor antagonist | |
WO2006018024A3 (en) | Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists | |
WO2003096983A3 (en) | Method of treating dyslipidemic disorders | |
EP1471909A4 (en) | Pharmaceutical composition and method for treating disorders of the central nervous system | |
WO2005107726A3 (en) | Method for the treatment of back pain | |
WO2003054216A3 (en) | Antibodies that immunospecifically bind to trail receptors | |
MXPA04001187A (en) | Interleukin-1 receptors in the treatment of diseases. | |
WO2005092009A3 (en) | Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders | |
WO2002097033A3 (en) | Antibodies that immunospecifically bind to trail receptors | |
WO2004000354A3 (en) | Method of treating the syndrome of lipodystrophy | |
WO2002015920A3 (en) | Treatment of hyperproliferative diseases | |
EP2543384A3 (en) | Treatment of conditions involving demyelination | |
WO2004024150A3 (en) | Mglu receptors antagonists for treating disorders associated with mglu receptors including addiction and depression | |
WO2004110380A3 (en) | Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents | |
EP1108426A3 (en) | Use of prostaglandin agonists to treat erectile dysfunction or impotence | |
EP1262197A3 (en) | Combination treatment for sleep disorders including sleep apnea | |
WO2003015690A3 (en) | Method for treating primary insomnia | |
WO2004064766A3 (en) | Method of treatment of conditions by administration of streptolysin o | |
WO2002053139A3 (en) | Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders | |
WO2004014307A3 (en) | Gal3 antagonists for the treatment of neuropathic pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 28/2002 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION. Free format text: IN PCT GAZETTE 28/2002 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION. |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |